Pantarhei to bid for Organon; Three biotechs file for bankruptcy;

@FierceBiotech: Dying breast cancer patient calls for personalized medicine. News | Follow @FierceBiotech

@JohnCFierce: No change in Arena's approach. Still pooh-poohing cancer link in rodents. And the FDA is just looking for reasons to reject obesity drugs. | Follow @JohnCFierce 

> According to the Dutch Financieele Dagblad, Pantarhei will bid for majority ownership in Merck's research unit Organon. Organon is also Netherlands-based, and has been in turmoil since September, when Merck announced it would look for alternatives, including selling the unit, instead of shutting its doors. Report

> In order to gain more financing, Mesoblast Limited issued nearly 25 million extra stock shares for AU$139 million, bringing their total cash reserves to AU$280 million. The company's growth strategy rests on its Cephalon partnership, orthopedic products and intravenous products for diabetes, lung and joint diseases. Mesoblast release

> Angiotech Pharmaceuticals has secured debtor-in-posession (DIP) financing from Wells Fargo Capital Finance. The credit could be worth up to $28 million. Angiotech release

> Three Manatee County, FL-based biotechs have filed for bankruptcy late last month. Organica Biotech, Pathway Holdings and Techno-Org filed for Chapter 11 reorganization separately on Jan. 25. News

And Finally... At Valentine's Day, the Thoroughbred industry's thoughts turn to the breeding shed, where farms try each year to create another Kentucky Derby winner. This year, Louisville biotech company CreoSalus is shipping out a new drug that could help increase a mare's chances of getting pregnant on the first attempt. Story